Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.
/ 1651 items
#XY↓
Neumora Halts Navacaprant Development After Phase 3 Depression Trials Fail
Neumora stopped navacaprant after failed depression trials, cut 35% jobs, shares fell, but keeps advancing 3 other drugs.
Elicio Stock Falls After Phase 2 Pancreatic Cancer Trial Misses Primary Endpoint
Elicio stock plunged after Phase 2 failed main goal, but showed cancer benefit in selected patients.
Twist Bioscience Stock Surges Toward $1 Billion Goal as Canaccord Joins Bullish Chorus
Canaccord is bullish on Twist Bioscience, citing AI-driven DNA tech growth, strong revenue gains, and upside to $90 target.
Traws Pharma Puts Phase 2 Influenza Trial on Hold After UK Regulator Feedback
Traws Pharma shares fell after delaying its Phase 2 human influenza challenge study due to negative feedback from the UK’s MHRA. The company is now advancing backup flu antiviral candidates.
Raymond James Bullish on Dianthus as Claseprubart Outperforms Expectations in Early CAPTIVATE Results
Raymond James reiterated its Strong Buy rating and $125 price target on Dianthus after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP.